Noel Maestre, PE, vice president of Life Sciences, and David Estape, technology manager Biotechnology at CRB discuss how virus response rewrote the playbook for vaccine response, but even more change is necessary to deal with emerging threats.
Across the world, governments and biopharma organisations are absorbing the lessons of the Covid-19 pandemic. With much of the world now in endemic protocols – managing the virus, yet wary of variants potentially in wait - there is an enormous amount to understand about what worked, and what didn’t, in the race to deliver effective life-saving vaccines and therapies.
As we move toward virus management, we marvel about everything it took to get us here. New ways of accelerating from R&D to manufacturing. New models for partnership and collaboration. A whole new mindset, which casts off our industry’s conservative nature in favour of more innovation, more speed, and more flexibility with the goal of more lives saved.